PharmaBlock Sciences Nanjing Inc Class A (300725.SZ) stock: key figures, P/E, revenue and dividend
Health Care · Pharmaceuticals · China · ISIN CNE1000035K5
PharmaBlock Sciences Nanjing Inc Class A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.69 bn CNY | 1.97 bn CNY |
| Gross profit | 582.74 m CNY | 608.45 m CNY |
| Operating income | 251.20 m CNY | 254.62 m CNY |
| EBIT | 311.17 m CNY | 241.83 m CNY |
| Net income | 219.54 m CNY | 183.74 m CNY |
| Diluted EPS – continuing operations | 1.10 CNY | 0.79 CNY |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About PharmaBlock Sciences Nanjing Inc Class A
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial manufacturing in China and internationally. It offers medicinal chemistry-oriented SAR/SPR tool kits for molecule design; building blocks enabled libraries, including fragment-based drug discovery, and mega virtual library screening to support the discovery of novel hit compounds; custom synthesis (FFS); and full time equivalent (FTE). The company also provides small molecule drug substance CDMO services, including optimal route scouting; FFS and FTE for process research and development of RSMs, intermediates, and APIs; impurity studies and synthesis; solid state chemistry; analytical development and quality control; cGMP manufacturing of intermediates and APIs; and CMC regulatory filing support. In addition, it offers small molecule DP CDMO services, such as candidate screening and selection, early development, full development, registration, and post-approval; and new modality services, including target protein degrader, peptide, oligonucleotide, and ADC services. PharmaBlock Sciences (Nanjing), Inc. was founded in 2006 and is based in Nanjing, the People's Republic of China.
More stocks
- OCULAR THERAPEUTIX, INC (OCUL)
- Peptron Inc (087010.KQ)
- Dom Development SA (DOM.WA)
- Changzhou Fusion New Material Co. Ltd. A (688503.SS)
- Northking Information Technology Co (002987.SZ)
- Ryerson Holding Corp (RYZ)
- Neinor Homes SA (HOME.MC)
- STEPAN CO (SCL)
- Pearl Abyss Corp (263750.KQ)
- Safestore Holdings PLC (SAFE.L)
- Shenzhen Colibri Technologies Co Ltd (002957.SZ)
- Tokai Carbon Korea Co. Ltd (064760.KQ)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.